MALLINCKRODT UK FINANCE LLP

Article lists affiliations and funding sources for researchers in nephrology and critical care from various institutions, including University of Minnesota, University of Chicago, King’s College London, and University of Washington. Funding sources include Novartis, Bioporto, Biomerieux, NIH, and others.

Complement inhibitors market is growing due to the complement system's role in rare and chronic diseases. Over 40 companies are developing 50+ pipeline inhibitors, including Gefurulimab, ANX005, DNTH103, and others. Recent milestones include Q32 Bio presenting ADX-097 data at ASN Kidney Week 2024 and ReAlta Life Sciences dosing the first patient in a Phase II study of RLS-0071.

The global peptide therapeutics market is projected to grow from $42.1B in 2023 to $56.2B by 2030, driven by technological advancements, increasing demand for targeted treatments, and the rising incidence of chronic diseases. Peptide therapeutics offer high specificity and low toxicity, making them attractive for treating conditions like cancer and diabetes. Innovations in peptide engineering and delivery systems are enhancing their efficacy and stability, expanding their therapeutic potential across various diseases.

The 'Migraine: Seven-Market Drug Forecast and Market Analysis' report, added to ResearchAndMarkets.com's offering, forecasts the migraine market in the US, France, Germany, Italy, Spain, the UK, and Japan to grow from $9.2 billion in 2023 to $16.4 billion by 2033, driven by a 6.0% CAGR. The report covers epidemiology, treatment options, unmet needs, pipeline analysis, and market competition.

The DEA approved Takeda Pharmaceuticals to increase Vyvanse production by 24% to address ongoing ADHD drug shortages, with a 13,478-pound increase including 3434 pounds for domestic and 10,313 pounds for foreign demand.

The U.S. DEA approved Takeda Pharmaceuticals to increase Vyvanse production by 24% due to ongoing ADHD drug shortages, with 13,478 pounds allocated for domestic and foreign demand.